FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileRadiopharm Theranostics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
RAD.AX
Radiopharm Theranostics Limited Stock AnalysisComprehensive stock analysis for Radiopharm Theranostics Limited (RAD.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisRAD.AX
RAD.AX
Radiopharm Theranostics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
RAD.AX
  1. Home
  2. Stocks
  3. Radiopharm Theranostics Limited

Radiopharm Theranostics Limited

🇦🇺RAD.AX•ASX

Radiopharm Theranostics Limited

🇦🇺RAD.AX•ASX

Your view on RAD.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Radiopharm Theranostics Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Riccardo Canevari
Headquarters
62 Lygon Street, Carlton, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Riccardo Canevari
Headquarters
62 Lygon Street, Carlton, VIC, AU
Description

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.

The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.

Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic.

The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Radiopharm Theranostics Limited. Starting points for Radiopharm Theranostics Limited: EPS -AUD 0.02, beta 0.80 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Radiopharm Theranostics Limited. Radiopharm Theranostics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Radiopharm Theranostics Limited. Trailing twelve-month EPS for Radiopharm Theranostics Limited stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis quarterSep 2025Next quarterDec 2025This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimate−AUD 0.01−AUD 0.01−AUD 0.01−AUD 0.01
Lowest estimate−AUD 0.01−AUD 0.01−AUD 0.02−AUD 0.02
Highest estimate−AUD 0.01−AUD 0.01−AUD 0.00−AUD 0.00
Number of analysts1111
A year ago——−AUD 0.02—
Growth vs a year ago——+35.9%—

Revenue estimates

TotalThis quarterSep 2025Next quarterDec 2025This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 12.14MAUD 1.00MAUD 2.33MAUD 2.64M
Lowest estimateAUD 12.14MAUD 1.00MAUD 1.16MAUD 205333.00
Highest estimateAUD 12.14MAUD 1.00MAUD 3.57MAUD 5.29M
Number of analysts1153
A year ago——AUD 2.77M—
Growth vs a year ago——−15.7%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Radiopharm Theranostics Limited. Radiopharm Theranostics Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold RAD.AX20 companies
Compare RAD.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ADO.AXAnteoTech LimitedBasic MaterialsChemicals - Specialty—
AGN.AXArgenica Therapeutics LtdHealthcareBiotechnology—
ATX.AXAmplia Therapeutics LimitedHealthcareBiotechnology—
CSX.AXCleanSpace Holdings LimitedHealthcareMedical - Devices—
CTE.AXCryosite LimitedHealthcareMedical - Diagnostics & Research—
CYP.AXCynata Therapeutics LimitedHealthcareBiotechnology—
DOC.AXDoctor Care Anywhere Group PLCHealthcareMedical - Healthcare Information Services—
NSB.AXNeuroScientific Biopharmaceuticals LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PREDQPredictive Discovery LimitedHealthcareOTC$2,996
PREV.CNPreveCeutical Medical Inc.HealthcareCNQ$11.7M
PRLDPrelude Therapeutics IncorporatedHealthcareNASDAQ$191.0M
PRMEPrime Medicine, Inc.HealthcareNASDAQ$694.9M
PRNAFAlterity Therapeutics LimitedHealthcareOTC$109.8M
PROKProKidney Corp.HealthcareNASDAQ$349.7M
PROTProteonomix, Inc.HealthcareOTC$791
PRQRProQR Therapeutics N.V.HealthcareNASDAQ$155.2M
PRRUFImmutep LimitedHealthcareOTC$368.0M
PRTAProthena Corporation plcHealthcareNASDAQ$428.8M
PRTCYPureTech Health plcHealthcareOTC—
PRVCFPreveCeutical Medical Inc.HealthcareOTC$10.1M
Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Radiopharm Theranostics Limited. Coverage tracks Radiopharm Theranostics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Radiopharm Theranostics Limited.

RAD.AX AnalysisWeak
Past
1
Growth
1
Health
5
Profit
1
Value
1